Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Rani Therapeutics Holdings (RANI) Return on Sales (2020 - 2025)

Historic Return on Sales for Rani Therapeutics Holdings (RANI) over the last 6 years, with Q3 2025 value amounting to 39.66%.

  • Rani Therapeutics Holdings' Return on Sales fell 820400.0% to 39.66% in Q3 2025 from the same period last year, while for Sep 2025 it was 39.66%, marking a year-over-year decrease of 820400.0%. This contributed to the annual value of 55.04% for FY2024, which is N/A changed from last year.
  • According to the latest figures from Q3 2025, Rani Therapeutics Holdings' Return on Sales is 39.66%, which was down 820400.0% from 43.67% recorded in Q2 2025.
  • Rani Therapeutics Holdings' Return on Sales' 5-year high stood at 42.37% during Q3 2024, with a 5-year trough of 74.06% in Q1 2025.
  • Its 5-year average for Return on Sales is 7.08%, with a median of 5.1% in 2021.
  • Its Return on Sales has fluctuated over the past 5 years, first soared by 452100bps in 2023, then crashed by -910300bps in 2025.
  • Quarter analysis of 5 years shows Rani Therapeutics Holdings' Return on Sales stood at 19.54% in 2021, then tumbled by -60bps to 31.27% in 2022, then soared by 135bps to 10.84% in 2023, then plummeted by -241bps to 15.29% in 2024, then crashed by -159bps to 39.66% in 2025.
  • Its last three reported values are 39.66% in Q3 2025, 43.67% for Q2 2025, and 74.06% during Q1 2025.